We examine the distribution of corporate capital and job creation relative to Europe’s established and emerging life sciences clusters
Our 2021 life sciences report puts the EMEA life sciences industry under the microscope, at a time when the business sector in Europe received its highest ever level of capital investment. Europe’s ageing demographic situation, coupled with the COVID-19 pandemic, has accelerated the need for further medicinal/vaccine research, pharmaceutical and medical device production.
In this report we examine the distribution of corporate capital and job creation relative to Europe’s established and emerging life sciences clusters, looking back at how this has changed in the last year, compared to the last 10 years. We identify the locational drivers and key players who have driven activity, the impact of their needs in terms of physical real estate requirements and how this impacts investors.